iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://www.ncbi.nlm.nih.gov/pubmed/23591366
Risks and benefits of testosterone therapy in older men - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;9(7):414-24.
doi: 10.1038/nrendo.2013.73. Epub 2013 Apr 16.

Risks and benefits of testosterone therapy in older men

Matthew Spitzer  1 , Grace Huang, Shehzad Basaria, Thomas G Travison, Shalender Bhasin
Affiliations
Review

Risks and benefits of testosterone therapy in older men

Matthew Spitzer et al. Nat Rev Endocrinol. 2013 Jul.

Abstract

In young men (defined as age<50 years) with classic hypogonadism caused by known diseases of the hypothalamus, pituitary or testes, testosterone replacement therapy induces a number of beneficial effects, for example, the development of secondary sex characteristics, improvement and maintenance of sexual function, and increases in skeletal muscle mass and BMD. Moreover, testosterone treatment in this patient population is associated with a low frequency of adverse events. Circulating testosterone levels decline progressively with age, starting in the second and third decade of life, owing to defects at all levels of the hypothalamic-pituitary-testicular axis. In cohort studies, testosterone levels are associated weakly but consistently with muscle mass, strength, physical function, anaemia, BMD and bone quality, visceral adiposity, and with the risk of diabetes mellitus, coronary artery disease, falls, fractures and mortality. However, the clinical benefits and long-term risks of testosterone therapy--especially prostate-related and cardiovascular-related adverse events--have not been adequately assessed in large, randomized clinical trials involving older men (defined as age>65 years) with androgen deficiency. Therefore, a general policy of testosterone replacement in all older men with age-related decline in testosterone levels is not justified.

PubMed Disclaimer

Comment in

Similar articles

  • Benefits and Risks of Testosterone Treatment of Older Men with Hypogonadism.
    Galbiati FF, Goldman AL, Gattu A, Guzelce EC, Bhasin S. Galbiati FF, et al. Urol Clin North Am. 2022 Nov;49(4):593-602. doi: 10.1016/j.ucl.2022.07.011. Epub 2022 Oct 7. Urol Clin North Am. 2022. PMID: 36309416 Review.
  • Testosterone therapy in older men: clinical implications of recent landmark trials.
    Grossmann M, Anawalt BD, Yeap BB. Grossmann M, et al. Eur J Endocrinol. 2024 Jul 2;191(1):R22-R31. doi: 10.1093/ejendo/lvae071. Eur J Endocrinol. 2024. PMID: 38917356 Review.
  • Hypotestosteronaemia in the aging male: should we treat it?
    Christe N, Meier CA. Christe N, et al. Swiss Med Wkly. 2015 Nov 24;145:w14216. doi: 10.4414/smw.2015.14216. eCollection 2015. Swiss Med Wkly. 2015. PMID: 26599486 Review.
  • Age-Related Changes in the Male Reproductive System.
    Bhasin S, Valderrábano RJ, Gagliano-Jucá T. Bhasin S, et al. 2022 Feb 10. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2022 Feb 10. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905229 Free Books & Documents. Review.
  • Benefits and risks of testosterone therapy in older men.
    Cardona Attard C, Fava S. Cardona Attard C, et al. Minerva Urol Nefrol. 2019 Jun;71(3):217-229. doi: 10.23736/S0393-2249.19.03301-0. Epub 2019 Jan 28. Minerva Urol Nefrol. 2019. PMID: 30700083 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81 - PubMed
    1. J Androl. 2003 May-Jun;24(3):299-311 - PubMed
    1. Am J Epidemiol. 1981 Dec;114(6):804-16 - PubMed
    1. J Clin Endocrinol Metab. 2010 Jun;95(6):2790-9 - PubMed
    1. Am J Epidemiol. 1997 Oct 15;146(8):609-17 - PubMed

LinkOut - more resources